Combination Chemotherapy with Pirarubicin (THP), Cyclophosphamide, Vincristine, and Prednisolone (VEP-THP Therapy) in the Treatment of Non-Hodgkin’s Lymphoma
作者:
Toshiyuki Takagi,
Chikara Sakai,
Masao Oguro,
期刊:
Oncology
(Karger Available online 1990)
卷期:
Volume 47,
issue 1
页码: 25-28
ISSN:0030-2414
年代: 1990
DOI:10.1159/000226780
出版商: S. Karger AG
关键词: Pirarubicin;Chemotherapy;combination;Non-Hodgkin’s lymphoma
数据来源: Karger
摘要:
Twenty-eight patients with non-Hodgkin’s lymphoma (NHL) were treated with a combination of (2XXX-R)-4′-o-tetrahydropyranyladriamycin (pirarubicin, THP), cyclophosphamide, vincristine, and prednisolone (VEP-THP therapy). Eleven (45.8%) of twenty-four evaluable patients achieved complete response (CR). CR rate (52.8%) was higher in the intermediate-grade histology group than in high- or low-grade group. Toxicity was generally acceptable although leukopenia less than 2,000/ul was observed in 17 (60.7%) of 28 patients. Clinical signs of cardiotoxicity were not observed and alopecia was mild. Therefore, VEP-THP therapy is useful as a first-line chemotherapy in the treatment of NHL, particularly for the patients with intermediate-grade histology. Higher CR rate and longer relapse-free survival can be expected by administering a greater dose of THP or employing a schedule of fractionated low do
点击下载:
PDF
(1499KB)
返 回